Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
DYN 
Dyne Therapeutics Inc (DYN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/12/2025: DYN (3-star) is a STRONG-BUY. BUY since 1 days. Profits (0.00%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $35.09
1 Year Target Price $35.09
| 7 | Strong Buy |
| 6 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 95.55% | Avg. Invested days 44 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 08/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.65B USD | Price to earnings Ratio - | 1Y Target Price 35.09 |
Price to earnings Ratio - | 1Y Target Price 35.09 | ||
Volume (30-day avg) 14 | Beta 1.08 | 52 Weeks Range 6.36 - 47.45 | Updated Date 08/12/2025 |
52 Weeks Range 6.36 - 47.45 | Updated Date 08/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.88 |
Earnings Date
Report Date 2025-07-28 | When - | Estimate -0.94 | Actual -0.97 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -35.45% | Return on Equity (TTM) -61.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1036196437 | Price to Sales(TTM) - |
Enterprise Value 1036196437 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -8.87 | Shares Outstanding 142264000 | Shares Floating 122664065 |
Shares Outstanding 142264000 | Shares Floating 122664065 | ||
Percent Insiders 0.49 | Percent Institutions 91.37 |
Upturn AI SWOT
Dyne Therapeutics Inc
Company Overview
History and Background
Dyne Therapeutics, Inc. (founded in 2017) is a biotechnology company focused on developing therapies for serious muscle diseases. It utilizes its FORCE platform to deliver oligonucleotides to muscle tissue.
Core Business Areas
- Muscle Disease Therapeutics: Development of oligonucleotide therapies for Duchenne Muscular Dystrophy (DMD), Myotonic Dystrophy type 1 (DM1), and Facioscapulohumeral Muscular Dystrophy (FSHD).
Leadership and Structure
Dyne is led by CEO John Cox. The organization has a management team with expertise in oligonucleotide therapeutics and muscle disease. The company has a board of directors providing strategic oversight.
Top Products and Market Share
Key Offerings
- DYN-101 (DMD): An investigational phosphorodiamidate morpholino oligomer (PMO) designed to skip exon 51 in DMD patients. It is currently in clinical trials. Competitors include Sarepta Therapeutics (SRPT) and Nippon Shinyaku.
- DYN-201 (DM1): An investigational antisense oligonucleotide (ASO) designed to reduce the levels of mutant DMPK RNA in DM1 patients. It is also in clinical trials. Competitors include Ionis Pharmaceuticals (IONS).
- DYN-301 (FSHD): An investigational ASO designed to reduce DUX4 expression in FSHD patients. The competitors here depend on the approach and treatment target.
Market Dynamics
Industry Overview
The muscle disease therapeutics market is characterized by unmet medical needs, high treatment costs, and increasing research activity. Gene therapies and oligonucleotide-based therapies are gaining traction.
Positioning
Dyne Therapeutics is positioned as a leader in developing next-generation oligonucleotide therapies using its FORCE platform to enhance delivery to muscle tissue. They are a mid-cap player competing with larger, established companies.
Total Addressable Market (TAM)
The TAM for muscle disease therapeutics is substantial, estimated in the billions of dollars. Dyne is targeting specific genetic subtypes of these diseases, positioning them to capture a meaningful share of the market.
Upturn SWOT Analysis
Strengths
- Proprietary FORCE platform for enhanced delivery
- Strong preclinical and early clinical data
- Experienced management team
- Focus on unmet medical needs in muscle diseases
- Strong IP position
Weaknesses
- Clinical trial risks and uncertainties
- Reliance on proprietary technology
- High R&D costs
- Competition from established pharmaceutical companies
- Limited commercial infrastructure
Opportunities
- Expansion into new muscle disease targets
- Partnerships with larger pharmaceutical companies
- Advancement of pipeline programs to market
- Potential for breakthrough therapies
- Positive clinical trial results
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from novel therapies
- Patent challenges
- Economic downturn affecting R&D funding
Competitors and Market Share
Key Competitors
- SRPT
- IONS
- HALO
- CRIS
Competitive Landscape
Dyne's FORCE platform offers a potential advantage in delivery, but it competes with established companies with greater resources and commercial infrastructure. The success of Dyne will depend on the clinical and commercial success of its key pipeline programs.
Growth Trajectory and Initiatives
Historical Growth: Dyne's growth has been primarily driven by advancing its pipeline programs and securing partnerships. It is difficult to assess historical growth from just this information.
Future Projections: Future growth depends on clinical trial successes, regulatory approvals, and commercialization of its therapies. Analyst estimates would be needed to provide specific growth projections.
Recent Initiatives: Recent initiatives include advancing DYN-101, DYN-201, and DYN-301 into later-stage clinical trials, expanding its research platform, and strategic partnerships.
Summary
Dyne Therapeutics is a biotechnology company focused on developing oligonucleotide therapies for muscle diseases. Its FORCE platform may provide it with a competitive advantage. The company's success depends on clinical trial outcomes. They must be aware of competitive pressure, and economic risks in the market and in R&D funding.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on your own research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Dyne Therapeutics Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2020-09-17 | CEO, President & Director Mr. John G. Cox M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 206 | Website https://www.dyne-tx.com |
Full time employees 206 | Website https://www.dyne-tx.com | ||
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.